Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01435928 · ClinicalTrials.gov registry record · Phase 3
PEARL Schizophrenia Maintenance
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 676
- Enrollment target
NCT01435928 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 676 participants.
The verdict
NCT01435928, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 676 participants
- Enrollment target
Study Summary
Lurasidone HCI is a compound that is FDA-approved for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that Lurasidone is effective in the long term maintenance treatment of schizophrenia.
Interventions
- DRUG Matching Placebo
- DRUG Lurasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 676 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01435928
The ClinicalTrials.gov registry entry for NCT01435928 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 676 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT01435928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01435928 about?
NCT01435928 is a clinical study titled "PEARL Schizophrenia Maintenance". Lurasidone HCI is a compound that is FDA-approved for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that Lurasidone is effective in the long term maintenance treatment of schizophrenia.
What is the current status of trial NCT01435928?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 676 participants. The study started on 2011-09. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01435928?
The interventions under investigation include: Matching Placebo (DRUG), Lurasidone (DRUG).
Who is sponsoring clinical trial NCT01435928?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.